Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

d party contractors for certain goods and services, and any inability of these third party manufacturers to manufacture products, or any failure of these third party contractors to provide these goods and services, in each case in accordance with its respective contractual obligations, could adversely affect Shire's ability to manage its manufacturing processes or to operate its business;
  • the development, approval and manufacturing of Shire's products is subject to extensive oversight by various regulatory agencies and regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
  • the actions of certain customers could affect Shire 's ability to sell or market products profitably and fluctuations in buying or distribution patterns by such customers could adversely impact Shire's revenues, financial conditions or results of operations;
  • investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire's activities in the highly regulated markets in which it operates may result in the distraction of senior management, significant legal costs and the payment of substantial compensation or fines;
  • adverse outcomes in legal matters and other disputes, including Shire's ability to obtain, maintain, enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire's revenues, financial condition or results of operations;
  • and other risks and uncertainties detailed from time to time in Shire's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.

    i. Fine J-D, Johnson  LB, Suchindran C, Gedde-DahI T (1999e) The Epidemiology of I
    '/>"/>

    SOURCE Shire plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
    2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
    3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
    4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
    5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
    6. Shire Changes its NASDAQ Ticker Symbol to SHPG
    7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
    8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
    9. Shire Reaches Agreement in Principle With U.S. Government
    10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
    11. ODT Forum Presents Regenerative Technologies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/26/2015)... Feb. 26, 2015 Protiviti ( www.protiviti.com ), ... of the Governance Portal , designed to increase ... compliance (GRC) tasks across multiple business units and projects. ... help customers better align their controls with the COSO ... ) requirements. In response to client feedback, Protiviti has ...
    (Date:2/26/2015)... 26, 2015  NuGene International, Inc. ("NuGene") (OTCQB: ... skin and hair rejuvenation, has announced that it ... record for investor relations and strategic communications. ... sales and diversification strategies – and we need ... shareholders," stated Ali Kharazmi CEO of NuGene when ...
    (Date:2/26/2015)... February 26, 2015 Already well respected ... line by expanding its Length Gauge offerings with new ... , Specifically, HEIDENHAIN’s pencil probe-style SPECTO length ... specification. Two new 1Vpp, 12mm stroke length variants ... applications. One is a variant with a weak spring, ...
    (Date:2/26/2015)... Feb. 26, 2015  Dyadic International, Inc. ("Dyadic") ... and proprietary technologies are used to develop, manufacture ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... results for year ending December 31, 2014 after ... will host a conference call that day at ...
    Breaking Biology Technology:Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3
    ... PRINCETON, N.J., June 8 Celator Pharmaceuticals today ... the extended therapeutic bioavailability and tumor cell selectivity ... presented at the 14th Congress of the European ... 2009 (Abstracts 1398 and 383). , , ...
    ... BEIJING, June 8 /PRNewswire-Asia-FirstCall/ ... "Yongye" or the "Company"), a,leading developer and distributor ... in the People,s Republic of China (PRC), today,announced ... Yongye,Nongfeng Biotechnology Co., Ltd. (,Yongye Nongfeng,), it has ...
    ... in US dollars , , QUEBEC CITY, June ... AEZS ; TSX: AEZ), a global biopharmaceutical company focused ... regaining from Ardana Biosciences Ltd. ("Ardana"), the worldwide rights ... AEZS-130, it has entered into an agreement with the ...
    Cached Biology Technology:Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress 2Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress 3Yongye Biotechnology International Receives License to Manufacture Products 2Yongye Biotechnology International Receives License to Manufacture Products 3AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130 2AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130 3
    (Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
    (Date:2/5/2015)... N.C. , Feb. 5, 2015  Marken is ... logistics company and has launched a new marketing campaign ... Logistics Organization (CLO).  The new campaign focuses on ... patient, protocol and shipments. The first headline ... , aligns Marken,s priorities with its client,s priorities. Marken ...
    (Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
    Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
    ... , NORWOOD, Mass. , ... metabolomics company developing novel clinical diagnostic tools for applications in personalized ... Series B financing. New investor Atlas Venture ( Waltham, MA ) ... ( Wayne, PA ), and Oxford Bioscience Partners ( Boston, MA ...
    ... number of scientists are merging methods and results from different ... team of researchers in a recent issue of Evolution ... new data, however, researchers who want to analyze previous findings ... the authors say. In a commentary piece in the journal ...
    ... fortuita , new to the Iberian Peninsula and to science. ... is also a new entry for Europe and is the ... Foliicolous lichens, symbiosis between fungi and algae, are organisms ... environments such as the Iberian Peninsula, outside of the tropics, ...
    Cached Biology News:Molecular Biometrics Closes $12.5 Million Series B Equity Funding 2Molecular Biometrics Closes $12.5 Million Series B Equity Funding 3Molecular Biometrics Closes $12.5 Million Series B Equity Funding 4Molecular Biometrics Closes $12.5 Million Series B Equity Funding 5Biologists merge methods, results from different disciplines to find new meaning in old data 2Biologists merge methods, results from different disciplines to find new meaning in old data 3A new species of lichen discovered in the Iberian Peninsula 2
    ... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,382-1) ... assistance. ID clarifier: barcoded Mfr ...
    ... Optically clear dishes with stacking feature for ... new product number, created to easily match Cornings ... order under the old Sigma-Aldrich number (Z70,947-6) or ... low binding surface Comp Dim: surface area 55 ...
    ... ,Kit containing Dermal Fibroblasts (Mouse/BalbC) and media. ... long-term culture, and is guaranteed to provide ... from the date supplied, when used with ... embryonic day 18.5 ,Applications: ,Cultivation: ...
    ...
    Biology Products: